Search results
Results From The WOW.Com Content Network
Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines. . Released in beta in November 2004, the Google Scholar index includes peer-reviewed online academic journals and books, conference papers, theses and dissertations, preprints, abstracts, technical reports, and other ...
The Internet Archive Scholar is a scholarly search engine created by the Internet Archive in 2020. As of February 2024 [update] , it contained over 35 million research articles with full text access.
The term 'inhibitor' is often used in a general sense to describe any compound used to prevent unwanted polymerisation, however these compounds are often divided into 'retarders' and 'true inhibitors'. A true inhibitor has a well defined induction period during which no noticeable polymerisation takes place. They are consumed during this period ...
Alexandra Elbakyan at a conference at Harvard (2010). Sci-Hub was created by Alexandra Elbakyan, who was born in Kazakhstan in 1988. [22] Elbakyan earned her undergraduate degree at Kazakh National Technical University [23] studying information technology, then worked for a year for a computer security firm in Moscow, then joined a research team at the University of Freiburg in Germany in 2010 ...
The search engine indexed over 260 million publications, [5] 88 million of which are journal articles. [5] Preliminary reviews by bibliometricians suggested the new Microsoft Academic Search was a competitor to Google Scholar, Web of Science, and Scopus for academic research purposes [6] [7] as well as citation analysis.
An inhibitor can reduce the effectiveness of a catalyst in a catalysed reaction (either a non-biological catalyst or an enzyme).E.g., if a compound is so similar to (one of) the reactants that it can bind to the active site of a catalyst but does not undergo a catalytic reaction then that catalyst molecule cannot perform its job because the active site is occupied.
The status of working papers and conference proceedings depends on the discipline; they are typically more important in the applied sciences. The value of publication as a preprint or scientific report on the web has in the past been low, but in some subjects, such as mathematics or high energy physics , it is now an accepted alternative.
Defactinib (INN, codenamed VS-6063) is an inhibitor of PTK2, also known as focal adhesion kinase (FAK), Pyk2, and MELK which was developed by Pfizer and licensed to Verastem Oncology as a potential treatment for solid tumors. Development for mesothelioma was discontinued in 2015 due to lack of efficacy in a placebo-controlled phase II trial.